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Abstract
The	rewarding	effect	of	opiates	 is	mediated	through	dissociable	neural	systems	 in	
drug	 naïve	 and	 drug‐dependent	 states.	Neuroadaptations	 associated	with	 chronic	
drug	use	are	similar	 to	 those	produced	by	chronic	pain,	 suggesting	 that	opiate	 re-
ward	could	also	 involve	distinct	mechanisms	 in	chronic	pain	and	pain‐naïve	states.	
We	tested	this	hypothesis	by	examining	the	effect	of	dopamine	(DA)	antagonism	on	
morphine	reward	in	a	rat	model	of	neuropathic	pain.Neuropathic	pain	was	induced	
in	male	Sprague‐Dawley	rats	through	chronic	constriction	(CCI)	of	the	sciatic	nerve;	
reward	was	assessed	in	the	conditioned	place	preference	(CPP)	paradigm	in	separate	
groups	at	early	(4‐8	days	post‐surgery)	and	late	(11‐15	days	post‐surgery)	phases	of	
neuropathic	pain.	Minimal	effective	doses	of	morphine	that	produced	a	CPP	in	early	
and	 late	phases	of	neuropathic	pain	were	6	mg/kg	and	2	mg/kg	 respectively.	The	
DA	D1	receptor	antagonist,	SCH23390,	blocked	a	morphine	CPP	 in	sham,	but	not	
CCI,	rats	at	a	higher	dose	(0.5	mg/kg),	but	had	no	effect	at	a	lower	dose	(0.1	mg/kg).	
The	DA	D2	receptor	antagonist,	eticlopride	(0.1	and	0.5	mg/kg),	had	no	effect	on	a	
morphine	CPP	in	sham	or	CCI	rats,	either	in	early	or	late	phases	of	neuropathic	pain.	
In	the	CPP	paradigm,	morphine	reward	involves	DA	D1	mechanisms	in	pain‐naïve	but	
not	chronic	pain	states.	This	could	reflect	increased	sensitivity	to	drug	effects	in	pain	
versus	no	pain	conditions	and/or	differential	mediation	of	opiate	reward	in	these	two	
states.
K E Y W O R D S
addiction,	analgesia,	antinociception,	aversion,	chronic	pain,	dependence,	opioid,	reward
1  | INTRODUC TION
Chronic	pain,	which	affects	20%–30%	of	the	population	 (Blyth	et	
al.,	2001;	Breivik,	Collett,	Ventafridda,	Cohen,	&	Gallacher,	2006;	
Johannes,	 Le,	 Zhou,	 Johnston,	 &	 Dworkin,	 2010;	 Schopflocher,	
Taenzer,	&	 Jovey,	2011),	 is	 commonly	 treated	with	opioid	analge-
sics.	Although	effective	 in	 the	short‐term,	 long‐term	use	of	 these	
drugs	 can	 lead	 to	 reduced	 analgesia	 (tolerance)	 (Christie,	 2008),	
hyperalgesia	(Mao,	2002),	and	addiction	(Contet,	Kieffer,	&	Befort,	
2004).	Diversion	 of	 prescription	 opioids	 exacerbates	 these	 prob-
lems	and	has	contributed	to	an	epidemic	of	drug	overdose	and	death	
throughout	North	America	 and	many	 parts	 of	 Europe	 (Volkow	&	
McLellan,	2016).	Thus,	there	is	a	pressing	need	to	develop	effective	
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treatments	 for	 chronic	 pain	 with	 low	 abuse	 potential	 (Evans	 &	
Cahill,	2016).
A	major	challenge	in	this	endeavor	is	that	chronic	pain,	itself,	al-
ters	 brain	 reward	 systems	 (Taylor,	 Becker,	 Schweinhardt,	 &	 Cahill,	
2016;	Trang	et	al.,	2015)	that	are	associated	with	addiction	(Volkow,	
Koob,	&	McLellan,	2016;	Wise,	2008).	For	example,	induction	of	neu-
ropathic	 pain	 in	 rats	 inhibits	 dopamine	 (DA)	 transmission	 from	 the	
ventral	tegmental	area	 (VTA)	to	the	nucleus	accumbens	(NAc),	with	
dysfunction	emerging	as	animals	transition	from	acute	to	chronic	pain	
(Taylor,	Castonguay,	&	Taylor,	2015).	Human	imaging	studies	confirm	
that	 chronic	 pain	 is	 associated	 with	 disruptions	 in	 mesolimbic	 DA	
function	 (Hagelberg,	Forssell,	&	Aalto,	2003;	Hagelberg,	Forssell,	&	
Rinne,	2003;	Wood,	Schweinhardt,	&	Jaeger,	2007);	these	alterations	
may	explain	differences	in	neural	mechanisms	that	mediate	morphine	
reward	in	chronic	pain	and	pain‐free	states	(Cahill	et	al.,	2013;	Ozaki,	
Narita,	&	Narita,	2002).	A	comparable	dissociation	has	been	observed	
in	drug‐naïve	and	drug‐dependent	rats	(Bechara,	Harrington,	Nader,	
&	Kooy,	1992),	with	the	rewarding	effect	of	morphine	mediated	by	DA	
D1	and	D2	receptors	in	opiate‐naive	and	opiate‐dependent	states,	re-
spectively	(Lintas,	Chi,	&	Lauzon,	2011).	Given	that	both	chronic	pain	
and	repeated	drug	exposure	alter	mesolimbic	DA	function,	the	same	
dissociation	may	be	evident	in	pain	and	pain‐free	conditions.
This	study	continued	our	previous	investigation	into	mechanisms	
of	morphine	reward	in	pain‐naive	and	chronic	pain	states	(Cahill	et	al.,	
2013),	specifically	testing	whether	DA	D1	and	D2	mechanisms	have	
distinct	 roles	 in	 these	 two	 processes.	 Reward	was	 assessed	 using	
the	conditioned	place	preference	 (CPP)	paradigm	and	chronic	pain	
was	induced	using	a	chronic	constriction	injury	(CCI)	model	of	neuro-
pathic	pain	(Bennett	&	Xie,	1988).	Neuropathic	pain	is	characterized	
by	allodynia	(pain	responses	to	previously	neutral	stimuli)	and	hyper-
algesia	(heightened	or	sensitized	pain	responses),	which	is	presented	
in	rats	as	a	change	in	threshold	to	sensory	stimuli	that	increases	in	
intensity	 across	 an	 8	 to	 12‐day	 period	 in	 rats.	 A	 time‐dependent	
change	 in	 sensory	 hypersensitivities	 reflect	 neuroadaptations	 fol-
lowing	nerve	injury,	with	distinct	biological	processes	mediating	pain	
responses	 in	 early	 and	 late	 phases	 of	NP	 pain	 (Asaoka,	 Kato,	 Ide,	
Amano,	&	Minami,	2018;	Kato,	 Ide,	&	Minami,	2016;	Kleinschnitz,	
Brinkhoff,	Zelenka,	Sommer,	&	Stoll,	2004).	We,	therefore,	examined	
the	rewarding	effect	of	morphine	at	 two	separate	time	points	 fol-
lowing	CCI	surgery	and	used	a	CPP	protocol	that	ensured	condition-
ing	and	CPP	testing	did	not	overlap	in	the	two	groups.	We	assessed	
the	role	of	DAergic	receptors	in	morphine	reward	by	administrating	
the	D1	antagonist,	SCH23390,	or	D2	antagonist,	eticlopride,	prior	to	
conditioning	using	doses	that	block	a	morphine	CPP	in	opiate‐naïve	
and	opiate‐dependent	states	(Lintas	et	al.,	2011).
2  | MATERIAL S AND METHODS
2.1 | Subjects
Three	hundred	and	three	male	Sprague‐Dawley	rats,	weighing	250–
350	 g	 (postnatal	 day	 51–58)	 were	 transported	 from	 the	 supplier	
(Charles	River	Laboratories,	Montreal,	QC)	on	a	Monday	morning	in	
boxes	containing	six	animals	each.	The	following	morning,	they	were	
moved	to	pair‐housing	in	polycarbonate	cages	(45.5	×	24	×	21	cm)	
with	beta	chip	bedding	(Northeastern	Products	Corp,	Warrensburg,	
NY)	 and	 a	 black,	 plastic	 tube	 (PVC	 piping	 ~7.5	 cm	 diameter)	 pro-
vided	as	enrichment.	Cages	were	kept	in	a	climate‐controlled	room	
(21°C)	on	a	reverse	12:12	hr	light	cycle	(lights	off	at	07:00	hr),	with	
humidity	 levels	 ranging	 from	20%	to	70%	across	seasons.	Animals	
had	ad libitum	access	to	standard	rat	chow	(Labdiet,	PMI	Nutrition	
International,	 Brentwood,	MO)	 and	water	 in	 their	 home	 cage;	 be-
havioral	 testing	was	conducted	during	 the	dark	cycle.	Animals	ha-
bituated	to	the	facility,	including	handling,	for	a	minimum	of	3	days	
prior	to	the	start	of	surgical	procedures.	Cages	were	cleaned	twice	
per	week	and	rats	were	handled	daily,	exclusively,	by	the	researcher	
conducting	the	experiment.	All	experiments	were	conducted	in	ac-
cordance	with	the	guidelines	for	the	ethical	use	of	animals	outlined	
by	the	Canadian	Council	on	Animal	Care	and	the	experiments	were	
approved	by	the	Queen's	University	Animal	Care	Committee.
2.2 | Apparatus
The	 CPP	 apparatus	 was	 made	 of	 plexiglass	 and	 consisted	 of	 two	
large	 compartments	 (46	 ×	 46	 ×	 30	 cm)	 connected	 by	 a	 tunnel	
(19	×	38	×	30	cm).	The	two	large	compartments	differed	in	wall	color	
(black	and	white	stripes	or	solid	white)	and	floor	texture	 (striated	or	
bumpy).	The	tunnel	walls	were	clear	and	the	floor	was	made	of	sheet	
metal,	spray	painted	with	a	matte	black	finish.	Guillotine	doors,	that	
could	be	raised	or	lowered,	separated	the	tunnel	from	each	compart-
ment.	 Cameras	were	mounted	 directly	 above	 each	 set	 of	 boxes	 so	
that	 the	 rats’	 movement	 throughout	 the	 entire	 compartment	 could	
be	monitored	and	recorded.	Movement	was	tracked	using	the	video	
tracking	software	EthoVisonXT	 (Noldus	 Information	Technology	ver-
sion	9.0.720	Wageningen,	The	Netherlands).	Data	were	analyzed	using	
IBMS	SPSS	Statistics	(Version	25)	and	Microsoft	Office	Excel	(2016);	
figures	were	produced	using	Prism	7	for	Windows	(Version	7.03).
2.3 | Surgery
Rats	 were	 randomly	 assigned	 to	 neuropathic	 or	 sham	 surgery	
groups;	neuropathic	pain	was	induced	through	CCI	of	the	sciatic	
Significance
This	 study	 is	 a	 continuation	of	our	 long‐term	 research	pro-
gram	examining	the	relationship	between	the	analgesic	and	
rewarding	effects	of	abused	drugs.	Using	a	clinically	relevant	
model	of	chronic	pain,	we	demonstrate	that	blockade	of	do-
pamine	D1	receptors	reduces	opiate	reward,	but	only	in	pain‐
naïve	states.	These	results	add	to	the	growing	 literature	on	
alterations	 to	 reward	 system	 function	 in	 chronic	 pain.	 Our	
study	 is	 timely	 given	 the	 current	 opioid	 epidemic	 and	 the	
pressing	 need	 to	 develop	 new	 therapeutic	 compounds	 for	
chronic	pain	with	minimal	abuse	potential.
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nerve	 (Bennett	&	Xie,	 1988).	 Prior	 to	 surgery,	 animals	 received	
liquid	acetaminophen	 (0.6	ml	of	32	mg/L	dose,	orally)	and	were	
then	 anesthetised	 under	 isoflurane	 (5	 L/min	 induction,	 2–3	 L/
min	maintenance).	All	animals	received	5	ml	of	Lactated	Ringer's	
Solution	by	subcutaneous	 (s.c.)	 injection.	The	 left	hind	 limb	was	
shaved	 and	 cleaned	with	 alcohol	 and	 Betadine	 solution.	 An	 in-
cision	 was	 made	 on	 the	 hind	 limb	 and	 the	 muscle	 layers	 were	
bluntly	dissected	with	scissors	to	expose	the	sciatic	nerve.	Using	
4‐0	 chromic	 gut	 suture	 thread,	 four	 ligatures	were	 tied	 loosely	
around	the	sciatic	nerve,	and	 the	muscle	and	skin	were	sutured	
with	Monocryl	3‐0	thread.	Animals	receiving	sham	surgeries	had	
skin	and	blunt	muscle	dissection	with	no	manipulation	of	the	sci-
atic	 nerve.	 Following	 surgery,	 all	 animals	were	 pair	 housed	 in	 a	
separate	recovery	room	for	3	days,	then	returned	to	their	original	
colony	housing.
2.4 | Drugs
Morphine	sulfate	was	supplied	by	Sandoz	Canada	Inc.	(Boucherville,	
QC);	naloxone	HCl	dithydrate,	SCH23390	(DA	D1	receptor	antago-
nist),	 and	eticlopride	 (DA	D2	 receptor	antagonist)	were	purchased	
from	 Sigma‐Aldrich	 (Milwaukee,	 WI).	 All	 drugs	 were	 dissolved	 in	
0.9%	physiological	sterile	saline,	which	constituted	the	vehicle	injec-
tions	(1	ml/kg).
2.5 | Behavioral procedures
2.5.1 | Establishing a morphine CPP in early and late 
phases of chronic pain
Separate	 groups	 of	CCI	 rats	were	 tested	 for	 a	morphine	CPP	 in	
early	 (n	=	8)	and	 late	phases	 (n	=	10)	of	chronic	pain	to	establish	
doses	 that	produced	a	CPP	 in	each	condition	 (post‐surgery	days	
4–8	and	11–15,	 respectively).	Prior	 to	 the	 first	CPP	session,	CCI	
and	sham	rats	were	placed	in	the	tunnel	and	had	access	to	all	three	
compartments	for	30	min	(habituation).	During	habituation,	there	
was	no	bias	to	one	conditioning	compartment	or	the	other.	Over	
the	next	4	days	(day	4–7	or	11–14	post‐surgery),	rats	received	two	
conditioning	sessions	per	day	 (separated	by	~9	hr)	 in	which	they	
were	 injected	with	morphine	 or	 vehicle	 and	 confined	 to	 one	 of	
the	large	compartments	for	30	min.	The	assignment	of	drug‐paired	
compartment	and	order	of	conditioning	sessions	were	counterbal-
anced	within	groups.
The	 lowest	 dose	 tested	 (2	 mg/kg)	 produced	 a	 CPP	 in	 a	 late	
[t(9)	=	8.413,	p	<	0.001],	but	not	an	early	[t(7)	=	1.385,	p	=	0.211],	
phase	of	chronic	pain.	 Increasing	 the	dose	 to	4	mg/kg	 (n	=	8)	was	
also	ineffective	[t(7)	=	1.562,	p	=	0.164];	6	mg/kg	(n	=	8)	produced	a	
CPP	in	early	phase	chronic	pain	[t(7)	=	6.489,	p	<	0.001].	Thus,	in	all	
subsequent	experiments,	rats	tested	for	a	CPP	during	early	and	late	
phases	of	chronic	pain	were	injected	with	6	and	2	mg/kg	morphine	
(s.c.),	respectively.	Data	from	the	effective	doses	in	this	initial	exper-
iment are included as controls in subsequent analyses.
2.5.2 | Withdrawal
To	confirm	that	the	CPP	dosing	protocol	did	not	induce	physical	de-
pendence,	a	separate	group	of	surgery‐naïve	rats	(n	=	8)	was	tested	
for	 opiate	withdrawal	 symptoms	before	 and	 after	morphine	 injec-
tions	of	the	higher	dose	(6	mg/kg	s.c.	per	day	×	4	days).	Baseline	(BL)	
behavior	was	assessed	in	an	open	field	(46	×	46	×	30	cm)	24	hr	prior	
to	first	injection;	naloxone	(1	mg/kg,	s.c.)	was	administered	2	hr	after	
the	 last	 morphine	 injection	 and	 naloxone‐precipitated	withdrawal	
was	determined	for	30	min	 following	naloxone	 injection.	Behavior	
was	video	recorded	and	withdrawal	symptoms	were	scored	accord-
ing	to	an	established	scale	(Schulteis,	Markou,	Gold,	Stinus,	&	Koob,	
1994)	that	includes	head	shakes,	wet	dog	shakes,	teeth	chattering,	
paw	tremors,	diarrhea,	and	mouthing.	The	number	of	times	each	be-
havior	occurred	in	10‐min	bins	was	calculated	over	the	30	min.	There	
was	 no	 difference	 in	withdrawal	 scores	 before	 or	 after	morphine	
treatment;	mean	counts	of	head	shakes,	wet	dog	shakes,	teeth	chat-
tering,	 paw	 tremors,	 and	diarrhea	were	 all	 <1	 across	 both	30‐min	
sessions	(see	Table	1).
2.5.3 | Effects of DA antagonism on a morphine CPP
The	effects	of	DA	antagonism	on	 the	development	of	a	morphine	
CPP	were	assessed	in	separate	groups	of	CCI	and	sham‐lesioned	rats	
in	early	and	last	phases	of	chronic	pain.	The	experimental	timeline	for	
each	drug	and	surgery	group	is	shown	in	Figure	1;	subject	numbers	
are	presented	in	Table	2	(total	n	=	197).	The	two	CCI	control	groups	
(i.e.,	 no	DA	antagonist)	 for	 the	early	phase	came	 from	 the	experi-
ment	establishing	morphine	dose	elicits	a	CPP	in	an	early	(6	mg/kg)	
TA B L E  1  Mean	counts	of	withdrawal	behaviors,	prior	to	and	following	morphine	treatment
Withdrawal measure
Pre‐morphine Post‐morphine
0–10 min 10–20 min 20–30 min 0–10 min 10–20 min 20–30 min
Head	shakes 0 0.13 0.13 0.38 0 0
Wet	dog	shakes 0 0 0 0 0 0.13
Teeth	chattering 0 0 0 0 0 0
Paw	tremors 0 0 0 0 0.25 0
Diarrhea 0 0 0 0 0 0
Mouthing 0.13 0 0.38 0 0.25 0
4  |     GRENIER Et al.
phase	of	chronic	pain	(described	above).	The	CCI	control	group	for	
the	late	phase	of	chronic	pain	came	from	a	group	that	received	an	in-
jection	of	saline	(1	ml/kg)	10	min	prior	to	receiving	morphine	(2	mg/
kg	s.c.).	The	role	of	DA	D1	and	D2	antagonism	on	morphine	reward	
in	early	and	late	phases	of	chronic	pain	was	assessed	by	administer-
ing	SCH23390	or	eticlopride	(0.1,	or	0.5	mg/kg	intraperitoneally,	i.p.)	
10	min	prior	to	each	morphine	injection	during	conditioning.	On	test	
day	(days	8	and	15	post‐surgery),	rats	were	placed	in	the	tunnel	and	
the	amount	of	time	spent	in	each	compartment	was	recorded	over	
30	min.	Half	of	the	animals	in	each	group	were	tested	in	the	morning	
and	half	in	the	afternoon.
2.5.4 | Effects of DA antagonism on nociceptive  
responses
All	 CCI	 and	 sham	 animals	 underwent	 nociceptive	 testing	 for	 me-
chanical	 allodynia,	 with	 testing	 conducted	 1	 day	 prior	 to	 surgery	
(BL)	and	then	4,	7,	10,	and	14	days	post‐surgery.	Figure	1	shows	the	
relationship	between	the	timing	of	nociceptive	testing	and	CPP	con-
ditioning.	When	the	two	protocols	overlapped,	nociceptive	testing	
was	 conducted	 prior	 to	 the	 first	 (day	 4	 post‐surgery)	 or	 after	 the	
last	(days	7	and	14	post‐surgery)	conditioning	session.	Nociceptive	
testing	on	days	7	and	14	occurred	either	~3.5	or	~12.5	hr	 after	 a	
drug	 injection	 (saline	or	morphine	with	or	without	DA	antagonist),	
depending	on	whether	animals	received	drug	prior	to	the	morning	
or	afternoon	session.	The	peak	analgesic	effect	of	morphine	(s.c.)	in	
rats	is	15–30	min	with	an	antinociceptive	half‐life	of	~2	hr	so	sensory	
testing	occurred	beyond	this	window	(Berkotitz,	Cerreta,	&	Spector,	
1974).	We	also	confirmed	that	there	was	no	significant	difference	in	
nociceptive	withdrawal	scores	on	days	7	and	14	for	animals	receiving	
drug	prior	to	morning	or	afternoon	conditioning	sessions	(ps	>	0.05).
All	 animals	 had	30–45	min	 habituation	 in	 the	 procedure	 room	
prior	to	the	 initiation	of	sensory	testing.	Mechanical	allodynia	was	
measured	using	von	Frey	filaments.	First,	animals	were	placed	on	top	
of	an	elevated	wire	grid	for	a	10‐min	habituation	period.	Then,	a	12	g	
(5.07)	filament	(Stoelting,	Wood	Dale,	IL)	was	applied	to	the	bottom	
F I G U R E  1  Experimental	timeline	for	nociceptive	and	conditioned	place	preference	(CPP)	testing.	Separate	groups	of	chronic	constriction	
injury	(CCI)	and	sham‐lesioned	rats	were	tested	for	a	morphine	CPP	in	early	or	late	phases	of	chronic	pain	(conditioning	4–7	and	11–14	days	
post‐surgery).	All	animals	were	tested	for	thermal	and	mechanical	nociceptive	responses	1	day	prior	to	surgery	(baseline)	as	well	as	4,	7,	10,	
and	14	days	post‐surgery
TA B L E  2  Subject	numbers	for	each	surgery	and	drug	group
Pain phase Surgery group Control
D1 antagonism D2 antagonism
SCH23390 Eticlopride
0.1 mg/kg 0.5 mg/kg 0.1 mg/kg 0.5 mg/kg
Early CCI n	=	8 n = 11 n = 12 n = 11 n = 10
Sham n	=	8 n = 10 n = 9 n = 9 n = 9
Late CCI n = 10 n = 11 n = 11 n = 10 n = 12
Sham n = 10 n	=	8 n = 9 n = 10 n = 9
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of	 the	 ipsilateral	 hind	paw	and	 the	number	of	withdrawals	per	10	
applications	was	recorded	for	each	animal.	All	CCI	rats	exhibited	a	
sustained	reduction	in	von	Frey	threshold	across	the	duration	of	an	
experiment,	and	no	data	were	excluded	from	subsequent	analyses.
2.5.5 | Effects of DA antagonism on place 
conditioning
To	determine	whether	D1	receptor	antagonism	may	affect	motiva-
tion,	CCI	and	sham	rats	(n	=	8	each)	were	tested	in	the	CPP	paradigm	
following	 conditioning	with	 SCH23390	 (0.5	mg/kg	 i.p.)	 and	 saline	
(1	ml/mg	s.c.),	using	the	protocol	described	previously	(i.e.,	no	mor-
phine	was	administered).	The	experiment	was	conducted	during	late	
phase	chronic	pain	 (i.e.,	 days	11–14	post‐surgery)	 to	coincide	with	
peak	nociceptive	responses	in	the	CCI	model.
2.5.6 | Effects of DA antagonism on morphine‐
induced antinociception
To	determine	whether	DA	D1	antagonism	blocked	a	morphine	CPP	
by	reducing	sensory	nociception,	separate	groups	of	CCI	and	sham‐
lesioned	rats	underwent	nociceptive	testing	in	early	and	late	phases	
of	chronic	pain	following	 injections	of	either	saline	 (1	ml/kg	 i.p)	or	
SCH233390	(0.5	mg/kg	i.p.)	administered	10	min	prior	to	morphine	
(6	or	2	mg/kg)	(n	=	6	each;	total	n	=	48).	Each	animal	was	tested	on	
the	 day	 prior	 to	 surgery	 (drug‐free)	 and	 then	 on	 four	 consecutive	
days	that	coincided	with	post‐surgery	days	and	times	of	CPP	con-
ditioning	sessions	 (i.e.,	days	4–7	and	11–14	 in	early	and	 late	phase	
chronic	pain).	Sensory	threshold	testing	was	initiated	10	min	follow-
ing	the	injection	of	morphine	and	was	completed	within	30	min.
As	 described	 previously,	 mechanical	 withdrawal	 thresholds	
were	assessed	as	the	number	of	withdrawals	per	10	applications	
of	a	12‐g	filament.	Ten	minutes	later,	animals	were	tested	for	ther-
mal	hyperalgesia	using	a	tail	flick	analgesiometer	(IITC	Life	Science	
Inc.,	Woodland	Hills,	 CA)	 that	 projects	 a	 beam	of	 light	 onto	 the	
rat's	 tail.	The	distal	5‐cm	portion	of	 the	 tail	was	blackened	with	
permanent	 marker	 to	 facilitate	 heat	 absorption.	 Heat	 intensity	
was	adjusted	to	elicit	tail	flick	latencies	between	2	and	3	s	with	a	
10‐s	cut	off	period.	The	tail	was	placed	under	the	heat	source	with	
the	 rat	gently	wrapped	 in	a	 towel;	 the	 time	to	 flick	 the	 tail	 from	
the	 heat	 source	 was	 recorded	 manually.	 The	 test	 was	 repeated	
10–15	min	 later	 and	 the	 average	 of	 the	 two	 latency	 scores	was	
used.
2.6 | Statistical analyses
Data	 from	 CPP	 experiments	 were	 analyzed	 using	 four	 separate	
three‐way	factorial	analyses	of	variances	(ANOVAs)	for	both	early	
(SCH23390,	eticlopride)	and	 late	 (SCH23390,	eticlopride)	phases	
of	chronic	pain.	Surgery	condition	(CCI,	sham),	DA	antagonist	dose	
(0,	 0.1,	 0.5	mg/kg),	 and	 side	 of	 CPP	 apparatus	 (drug‐paired,	 sa-
line‐paired)	were	 included	 as	 between‐subjects	 factors.	 A	 priori	
planned	orthogonal	comparisons	were	calculated	to	compare	the	
amount	 of	 time	 spent	 in	 drug‐	 and	 saline‐paired	 compartments	
during	 testing.	These	a	priori	 tests	are	used	 to	analyze	a	 limited	
number	of	predicted	hypotheses.	The	primary	advantage	of	con-
ducting	planned	orthogonal	 contrasts	 is	 that	 these	minimize	 the	
number	 of	 comparisons	 to	 those	 of	 interest,	 based	 on	 specific	
hypotheses	(e.g.,	CCI	rats	administered	 low‐dose	SCH	will	spend	
more	 time	 in	 the	morphine‐paired	compartment	 than	 the	saline‐
paired	 compartment).	 Because	 each	 comparison	 is	 independent	
and	tests	a	unique	hypothesis,	it	can	be	carried	out	regardless	of	
the	outcome	of	the	overall	ANOVA	and	no	correction	is	made	for	
using	multiple	tests.	As	such,	a	5%	risk	of	type	I	error	is	accepted	
for	each	comparison.	Planned	comparisons	were	used	rather	than	
an	overall	three‐way	ANOVA	with	post	hoc	comparisons	because	
main	effects	do	not	yield	any	meaningful	information	in	this	analy-
sis	 (e.g.,	the	factor	“drug”	reflects	a	comparison	of	the	combined	
time	 in	 drug‐	 and	 saline‐paired	 compartments	 across	 surgery	
groups).	In	addition,	a	three‐way	ANOVA	on	our	data	would	yield	
28	post	hoc	comparisons,	requiring	a	correction	(and	justification)	
for	family‐wise	error.	More	importantly,	the	only	post	hoc	compar-
isons	that	would	be	meaningful	 in	this	analysis	are	exactly	those	
that	we	identify	in	the	planned	comparisons	analysis:	time	spent	in	
drug‐	versus	saline‐paired	compartment	for	each	group.
Using	 planned	 orthogonal	 comparison	 to	 analyze	 CPP	 data	
eliminates	 the	 possibility	 of	 comparing	 group	 differences	 in	 the	
magnitude	of	a	CPP.	To	deal	with	this	 issue,	we	created	the	vari-
able,	difference	score,	which	was	calculated	as	time	spent	in	mor-
phine‐paired	minus	 saline‐paired	 compartments	 for	 each	 group.	
These	difference	scores	were	compared	between	surgery	groups	
in	 the	 early	 and	 late	 phases	 of	 chronic	 pain	 experiments	 using	
independent	 samples	 t	 tests.	 In	 cases	 where	 assumptions	 were	
violated,	 we	 used	 a	 bootstrapped	 independent	 samples	 t test 
(number	 of	 samples	 =	 10,000),	 which	 is	 a	 non‐parametric	 alter-
native.	This	tests	samples	with	replacement	to	empirically	derive	
a	 null	 hypothesis	 distribution	 of	 the	 mean	 differences	 between	
groups.	 If	 the	overall	mean	difference	between	groups	 falls	out-
side	of	the	95%	percentile	corrected	confidence	interval	(CI)	of	the	
differences,	the	null	hypothesis	is	rejected.
Outliers,	normality,	and	homogeneity	of	variances	were	assessed	
using	 boxplots,	 the	 Shapiro–Wilk	 test,	 and	 Levene's	 test,	 respec-
tively.	Any	violations	are	presented	in	the	Results	section.	Outliers	
were	not	excluded	from	further	data	analysis.	Additionally,	we	have	
not	 corrected	 for	 non‐normality	 or	 violations	 of	 homogeneity	 of	
variance,	as	ANOVAs	are	relatively	robust	to	these	violations,	partic-
ularly	when	samples	sizes	are	approximately	equal	(Glass,	Peckham,	
&	Sanders,	1972).
Data	 from	mechanical	 and	 thermal	 nociceptive	 tests	were	 an-
alyzed	 using	 separate	 mixed‐model	 repeated	 measures	 ANOVAs,	
which	 assess	 statistically	 significant	 differences	 between	 means	
of	 independent	groups.	 In	this	analysis,	surgery	(CCI	vs.	sham)	and	
drug	dose	were	 included	as	between‐subject	 factors	 and	day	was	
included	 as	 a	 within‐subjects	 (repeated)	 factor.	 Tukey's	 post	 hoc	
analysis	 was	 performed	 for	 multiple	 comparisons.	 Sphericity	 was	
assessed	using	Mauchly's	test	and	violations	were	corrected	using	a	
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Greenhouse–Geisser	correction.	Levene's	F	test	was	used	to	exam-
ine	the	assumptions	of	homogeneity	of	variance	and	Shapiro–Wilk	
test	assessed	normality.	We	lacked	sufficient	prior	data	for	an	a	pri-
ori	power	analysis;	thus	we	based	our	sample	size	on	previous	stud-
ies	using	similar	methods	(Cahill	et	al.,	2013).
3  | RESULTS
3.1 | Effects of DA antagonism on a morphine CPP
3.1.1 | Morphine CPP in early phase chronic pain
As	 shown	 in	 Figure	 2a	 and	 confirmed	 by	 a	 series	 of	 planned	
orthogonal	 comparisons,	 morphine	 (6	 mg/kg	 s.c.)	 produced	
a	 robust	CPP	 in	 both	 sham,	 t(104)	 =	 4.048,	p	 <	 0.001,	 and	CCI,	
t(104)	=	8.489,	p	<	0.001,	 rats	during	 the	early	phase	of	chronic	
pain.	The	magnitude	of	the	effect	was	 larger	 in	CCI	rats,	but	did	
not	 reach	 a	 statistical	 significance	 (bootstrapped	 independent	
samples	 t	 test,	Mdiff	 =	 −472.525,	 95%	CIdiff	 =	 −980.779–35.730,	
p	>	0.05).	A	morphine	CPP	was	blocked	in	sham	rats	by	the	higher	
dose	of	SCH23390,	t(104)	=	1.008,	p	=	0.315,	but	remained	intact	
in	all	other	groups	[sham	0.1	mg/kg:	t(104)	=	2.392,	p	=	0.019;	CCI	
0.1	mg/kg	t(104)	=	4.446,	p	<	0.001;	CCI	0.5	mg/kg:	t(104)	=	6.130,	
p	<	0.001]	(Figure	2b).	For	this	ANOVA,	there	were	three	outliers	
that	were	greater	than	1.5	times	the	interquartile	range	(IQR)	(CCI,	
0	 mg/kg,	 drug	 and	 saline‐paired	 sides;	 sham,	 0.1	 mg/kg,	 drug‐
paired	side).	Normality	was	violated	 in	one	group	 (CCI,	0	mg/kg,	
saline‐paired	 side),	 Shapiro–Wilk's	W	 =	0.737,	df	 =	8,	p = 0.006. 
The	 assumption	 of	 homogeneity	 of	 variance	 was	 also	 violated,	
p	 =	 0.039.	We	 used	 a	 bootstrapped	 independent	 samples	 t test 
to	compare	the	magnitude	of	morphine	CPP	in	CCI	and	sham	rats	
because	there	was	one	outlier	greater	 than	1.5	times	the	 IQR	 in	
the	CCI	group.
Eticlopride	 had	 no	 effect	 on	 a	morphine	 CPP	 in	 any	 of	 the	
groups	[sham	0.1	mg/kg:	t(98)	=	5.414,	p	<	0.001;	CCI	0.1	mg/kg:	
t(98)	=	7.338,	p	<	0.001;	sham	0.5	mg/kg	t(98)	=	3.801,	p < 0.001; 
CCI	 0.5	 mg/kg:	 t(98)	 =	 6.305,	 p	 <	 0.001]	 (Figure	 2c).	 In	 this	
ANOVA,	there	were	four	outliers	that	were	greater	than	1.5	times	
the	 IQR	(CCI,	0	mg/kg,	drug‐	and	saline‐paired	sides;	2	×	sham,	
0.1	mg/kg,	drug‐paired	side).	Normality	was	violated	in	one	group	
(CCI,	0	mg/kg,	saline‐paired	side),	Shapiro–Wilk	=	0.737,	df	=	8,	p 
= 0.006.
3.1.2 | Morphine CPP in late phase chronic pain
Morphine	(2	mg/kg	s.c.)	produced	a	CPP	during	late	phases	of	chronic	
pain	in	both	sham,	t(106)	=	6.158,	p	<	.001,	and	CCI,	t(106)	=	8.285,	
p	<	0.001,	rats	(Figure	3a).	Again,	the	size	of	the	CPP	was	larger	in	CCI	
than	sham	rats,	although	the	effect	did	not	reach	statistical	signifi-
cance	(bootstrapped	independent	samples	t	test,	Mdiff	=	−198.243,	
95%	CIdiff	=	−479.149–82.672,	p	>	0.05).	As	previously,	 the	higher	
dose	of	SCH23390	blocked	the	effect,	but	only	in	sham	rats	[sham	
0.1	mg/kg:	t(106)	=	2.396,	p	=	0.018;	sham	0.5	mg/kg:	t(106)	=	0.187,	
p	=	0.851;	CCI	0.1	mg/kg	t(106)	=	5.729,	p	<	0.001;	CCI	0.5	mg/kg:	
t(106)	=	3.890,	p	<	0.001]	(Figure	3b).
There	were	three	outliers	in	this	ANOVA—two	were	>1.5	times	
the	IQR	(sham,	0	mg/kg,	saline‐paired	side;	sham,	0.5	mg/kg,	drug‐
paired	side)	and	one	was	>3	times	the	IQR	(sham,	0.5	mg/kg,	drug‐
paired	 side).	Normality	was	violated	 in	 three	groups	 (sham,	0	mg/
kg,	 saline‐paired:	 Shapiro–Wilk	=	0.814,	df	 =	10,	p	 =	0.021;	 sham,	
0.1	mg/kg,	drug‐paired:	Shapiro–Wilk's	W	=	0.820,	df	=	8,	p	=	0.047;	
sham,	 0.5	 mg/kg,	 drug‐paired:	 Shapiro–Wilk's	 W	 =	 0.760,	 df	 =	 9,	
p	 =	 0.007).	 A	 bootstrapped	 independent	 samples	 t test was used 
to	compare	 the	magnitude	of	morphine	CPP	 in	CCI	and	sham	rats	
F I G U R E  2  Effects	of	dopamine	(DA)	antagonism	on	a	
conditioned	place	preference	to	morphine	in	an	early	phase	of	
chronic	pain	(days	4–8	post‐surgery).	Bars	represent	mean	(±SD)	
time	spent	in	drug‐	and	saline‐paired	compartments	over	a	30‐min	
drug‐free	test.	Separate	groups	of	chronic	constriction	injury	(CCI)	
and	sham‐lesioned	rats	were	conditioned	with	morphine	(6	mg/
kg)	(a),	morphine	plus	the	DA	D1	antagonist,	SCH233390	(b),	or	
morphine	plus	the	DA	D2	antagonist,	eticlopride	(c).	Antagonist	
drugs	were	administered	10	min	prior	to	morphine	at	doses	of	0.1	
or	0.5	mg/kg.	Data	points	represent	individual	rats
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because	there	was	one	outlier	greater	than	1.5	times	the	IQR	in	the	
sham	group.
As	with	early	phases	of	chronic	pain,	eticlopride	had	no	effect	
on	a	morphine	CPP	[sham	0.1	mg/kg:	t(110)	=	5.644,	p	<	0.001;	CCI	
0.1	mg/kg:	t(110)	=	6.163,	p	<	0.001;	sham	0.5	mg/kg	t(110)	=	4.828,	
p	<	0.001;	CCI	0.5	mg/kg:	t(110)	=	5.709,	p	<	0.001]	(Figure	3c).	Five	
outliers	were	detected	as	being	greater	than	1.5	times	the	IQR	(CCI,	
0.5	mg/kg,	drug‐paired	side;	sham,	0	mg/kg,	drug‐paired	side;	sham,	
0.1	mg/kg,	saline‐paired	side;	2	×	sham,	0.5	mg/kg,	drug‐paired	side).	
Normality	was	violated	in	one	group	(sham,	0	mg/kg,	saline‐paired:	
Shapiro–Wilk	=	0.814,	df	=	10,	p	=	0.021).
3.2 | Effects of DA antagonism 
on nociceptive responses
3.2.1 | Nociceptive responses in early phase 
chronic pain
Repeated	measures	ANOVAs	and	data	presented	 in	Figure	4	con-
firm	that	CCI	surgery	induced	mechanical	allodynia,	with	mechanical	
stimulus	 responses	 increasing	across	 testing	 in	CCI,	but	not	 sham,	
rats	treated	with	morphine	plus	SCH23390,	surgery	×	day	interac-
tion: F(20,	208)	=	35.058,	n	=	58,	p	<	0.001	(Figure	4a)	and	morphine	
plus	eticlopride,	F(20,	196)	=	23.456,	n	=	55,	p	<	0.001	(Figure	4b).	
All	testing	was	conducted	in	a	drug‐free	state.	In	addition	to	signifi-
cant	differences	in	withdrawal	scores	of	CCI	and	sham	animals	on	all	
post‐surgery	testing	days,	post	hoc	tests	revealed	lower	mechanical	
responses	on	day	14	in	CCI	animals	treated	with	either	SCH23390	
(0.5	mg/kg;	p	=	0.008)	or	eticlopride	(0.1	and	0.5	mg/kg;	p = 0.001 
and p	<	0.001,	respectively),	compared	to	saline	controls.
3.2.2 | Nociceptive responses in late phase 
chronic pain
Mechanical	allodynia	also	increased	post‐surgery	in	CCI,	but	not	in	
sham,	rats	that	were	tested	for	a	CPP	during	a	last	phase	of	chronic	
pain.	 These	 effects	 were	 verified	 by	 a	 mixed‐model	 repeated	
measures	ANOVA,	which	 revealed	a	 significant	 surgery	×	 time	 in-
teraction	 in	 both	morphine	 plus	 SCH23390,	 F(20,	 212)	 =	 14.905,	
n	 =	59,	p	 <	0.001	 (Figure	4c)	 and	morphine	plus	 eticlopride,	F(20,	
220)	=	23.147,	n	=	61,	p	<	0.001	(Figure	4d)	groups.	There	was	no	evi-
dence	that	SCH23390	altered	mechanical	sensory	responses	in	CCI	
rats	(i.e.,	post	hoc	comparisons	of	CCI	saline	and	SCH23390	groups,	
0.1	mg/kg:	p	=	0.985;	0.5	mg/kg:	p	=	0.997),	whereas	CCI	rats	treated	
with	 eticlopride	 (0.1	mg/kg)	 showed	 lower	 responses	 than	 saline‐
treated	rats	on	day	14	(p	=	0.004).	In	both	early	and	late	phases	of	
chronic	pain,	normality	was	violated	in	sham‐lesioned	groups	receiv-
ing	saline,	W	=	0.552,	p	<	0.001,	reflecting	the	fact	that	some	animals	
in	these	groups,	as	expected,	displayed	no	withdrawal	response	to	
the	filaments.
3.3 | Effects of DA D1 antagonism on place 
conditioning
Figure	 5	 shows	 that	 DA	 D1	 antagonism	 had	 no	 motivational	 ef-
fects	on	its	own.	Neither	CCI,	t(14)	=	−1.334,	p	=	0.203,	nor	sham,	
t(14)	=	−1.565,	p	=	0.140,	rats	developed	a	preference	for,	or	an	aver-
sion	to,	a	compartment	previously	paired	with	SCH23390	(0.5	mg/
kg).
3.4 | Effects of DA D1 antagonism on morphine‐
induced antinociception
Data	presented	in	Figure	6,	analyzed	with	a	mixed‐model	repeated	
measures	ANOVA,	confirmed	that	DA	D1	antagonism	had	no	effect	
F I G U R E  3  Effects	of	dopamine	(DA)	antagonism	on	a	
conditioned	place	preference	to	morphine	in	a	late	phase	of	chronic	
pain	(days	11–15	post‐surgery).	Bars	represent	mean	(±SD)	time	
spent	in	drug‐	and	saline‐paired	compartments	over	a	30‐min	drug‐
free	test.	Separate	groups	of	chronic	constriction	injury	(CCI)	and	
sham‐lesioned	rats	were	conditioned	with	morphine	(2	mg/kg)	plus	
saline	(a),	morphine	(2	mg/kg)	plus	the	DA	D1	antagonist,	SCH233390	
(b),	or	morphine	(2	mg/kg)	plus	the	DA	D2	antagonist,	eticlopride	
(c).	Antagonist	drugs	were	administered	10	min	prior	to	morphine	at	
doses	of	0.1	or	0.5	mg/kg.	Data	points	represent	individual	rats
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on	the	antinociceptive	properties	of	morphine	in	either	CCI	or	sham‐
lesioned	rats.	The	ANOVAs	revealed	significant	time	x	treatment	in-
teractions	for	withdrawal	scores	in	early,	F(12,	80)	=	6.091,	n	=	24,	
p	<	0.001	(Figure	6a),	and	late,	F(12,	80)	=	9.721,	n	=	24,	p < 0.001 
(Figure	6c),	phases	of	chronic	pain,	with	similar	results	in	the	tail	flick	
test: F(12,	 80)	 =	7.416,	n	 =	24,	p < 0.001 and F(12,	 80)	 =	10.320,	
n	=	24,	p	<	0.001	(Figure	6b,d).	These	patterns	reflect	increased	no-
ciceptive	 responses	of	CCI	 compared	 to	 sham‐lesioned	 rats	 and	 a	
decline	in	the	effectiveness	of	morphine	across	sessions	(i.e.,	toler-
ance).	 Tukey's	 post	 hoc	 tests	 confirmed	 no	 significant	 differences	
between	 morphine	 plus	 saline	 versus	 morphine	 plus	 SCH	 23390	
groups	on	any	measure	(final	test	day	of	early	and	late	phase	chronic	
pain:	withdrawal	scores,	p	=	0.937	and	p	=	0.971,	and	tail	flick	laten-
cies,	p	=	0.794	and	p	=	0.984).
4  | DISCUSSION
A	primary	 finding	 in	our	 study	 is	 that	blockade	of	DA	D1	 receptors	
disrupts	a	morphine	CPP	in	sham‐lesioned,	but	not	CCI,	rats.	The	ef-
fect	cannot	be	attributed	to	disruptions	in	memory	processes	as	neu-
ropathic	rats	treated	with	a	D1	antagonist	displayed	a	CPP.	Nor	did	the	
drug	produce	motivational	effects	on	its	own,	suggesting	that	the	im-
pact	is	specific	to	morphine	reward	in	pain‐naïve	states.	These	findings	
parallel	 evidence	 that	DA	D1	antagonism	 reduces	morphine	 reward	
in	opiate‐naïve,	 but	not	opiate‐dependent,	 rats	 (Lintas	 et	 al.,	 2011).	
In	contrast,	D2	receptor	blockade	did	not	disrupt	a	morphine	CPP	in	
neuropathic	 rats,	 suggesting	 that	alterations	 in	 reward	processing	 in	
drug‐dependent	states	(Lintas	et	al.,	2011)	and	chronic	pain	may	not	
overlap.	Notably,	opiate	treatment	in	our	experiment	did	not	elicit	any	
sign	of	withdrawal	and	was	dramatically	lower	than	the	protocols	used	
to	establish	morphine	dependence	 in	other	CPP	 studies	 (Laviolette,	
F I G U R E  4  Nociceptive	responses	of	chronic	constriction	injury	(CCI)	and	sham‐lesioned	rats	tested	for	a	morphine	conditioned	place	
preference	(CPP)	during	early	(a,	b)	and	late	(c,	d)	phases	of	chronic	pain.	Data	points	represent	mean	(±SD)	number	of	paw	withdrawals	(/10)	
to	application	of	a	von	Frey	filament	in	a	test	of	mechanical	allodynia.	Dotted	lines	indicate	CPP	conditioning	sessions	during	early	and	late	
phases	of	chronic	pain	in	which	animals	were	injected	daily	with	morphine	(2	or	6	mg/kg)	combined	with	the	dopamine	(DA)	D1	antagonist,	
SCH233390	(a,	c),	or	the	DA	D2	antagonist,	eticlopride	(b,	d).	Baseline	(BL)	testing	occurred	1	day	prior	to	surgery	and	nociceptive	testing	
was	conducted	in	a	drug‐free	state
F I G U R E  5  Effects	of	dopamine	D1	antagonism	on	place	
conditioning	in	a	late	phase	of	chronic	pain	(11–15	days	post‐
surgery).	Bars	represent	mean	(±SD)	time	spent	in	SCH23390‐	and	
saline‐paired	compartments	over	a	30‐min	drug‐free	test.	Separate	
groups	of	chronic	constriction	injury	(CCI)	and	sham‐lesioned	rats	
were	injected	with	SCH233390	(0.5	mg/kg)	or	saline,	administered	
10	min	prior	to	conditioning	sessions
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Nader,	&	Van	der	Kooy,	2002).	Thus,	pharmacological	systems	of	mor-
phine	reward	appear	to	be	distinct	in	states	of	drug	dependence	and	
chronic	pain,	at	least	as	measured	in	the	CPP	paradigm.
The	 fact	 that	DA	D1	antagonism	had	no	effect	on	a	morphine	
CPP	 in	CCI	 rats	 strengthens	 the	 contention	 that	 neuropathic	pain	
alters	DAergic	mechanisms	of	 opiate	 reward	 (Asaoka	 et	 al.,	 2018;	
Taylor	 et	 al.,	 2016).	This	pain‐induced	 shift	 in	neuropharmacologi-
cal	systems	of	drug	reward	likely	involves	the	alterations	in	DA	sig-
naling	in	the	VTA	to	NAc	pathway	(Taylor	et	al.,	2015).	Subsequent	
studies	have	shown	that	chronic	neuropathic	pain	decreases	basal	
DA	 release	 within	 the	 NAc,	 which	 is	 positively	 correlated	 with	 a	
decrease	 in	VTA	dopaminergic	cell	 firing	 (Ren,	Centeno,	&	Berger,	
2016).	 Importantly,	 this	 latter	 study	 suggested	 that	DA	hypofunc-
tion	was	at	 least	partially	responsible	for	pain	hypersensitivities	 in	
neuropathic	 pain	 as	 treatment	with	 levodopa	 attenuated	mechan-
ical	 tactile	 allodynia.	 Additionally,	 optogenetic	 activation	 of	 DA	
neurons	attenuated	thermal	hyperalgesia	in	a	model	of	neuropathic	
pain	 (Watanabe,	Narita,	 &	Hamada,	 2018),	 demonstrating	 the	 im-
portance	of	DA	circuitry	in	chronic	pain	states.	In	contrast,	optoge-
netic	inhibition	of	VTA‐NAc	DA	projection	neurons	reversed	thermal	
hyperalgesia	in	a	neuropathic	pain	model	(Zhang,	Qian,	&	Li,	2017).	
It	 is	 unclear	why	 these	 latter	 studies	 report	 opposite	 findings,	 al-
though	the	differences	in	outcomes	may	be	due	to	the	topograph-
ical	organization	of	heterogeneous	DA	neurons,	where	cells	 in	 the	
dorsal	and	ventral	VTA	are	inhibited	or	excited	by	noxious	electrical	
stimuli,	respectively	(Matsumoto	&	Hikosaka,	2009).	It	is	also	possi-
ble	that	D1	antagonism	is	having	an	effect	at	other	neural	sites,	such	
as	the	central	amygdala	(Zarrindast,	Rezayof,	Sahraei,	Haeri‐Rohani,	
&	Rassouli,	2003)	or	hippocampus	 (Rezayof,	Zarrindast,	Sahraei,	&	
Haeri‐Rohani,	2003).	Regardless,	the	inability	of	the	D1	antagonist	
to	block	morphine	reward	in	the	CCI	neuropathic	pain	model	in	our	
study	supports	 the	hypothesis	 that	morphine	 is	producing	a	place	
preference	via	negative	reinforcement	(rather	than	positive	motiva-
tional	valence)	by	alleviating	activation	of	nociceptive	circuitry.
Behavioral	studies	examining	pain‐induced	alterations	in	reward	
processing	 have	 also	 produced	 conflicting	 results.	 Some	 evidence	
points	to	increased	reward	in	neuropathic	pain;	a	morphine	CPP	is	
expressed	at	lower	doses	in	CCI,	compared	to	pain‐naïve,	rats	(Cahill	
et	al.,	2013;	Woller	et	al.,	2012)	and	inflammatory	pain	increases	the	
motivation	to	self‐administer	high	doses	of	heroin	(Hipolito,	Wilson‐
Poe,	 &	 Campos‐Jurado,	 2015).	 On	 the	 other	 hand,	 the	 rewarding	
effect	of	morphine	is	reduced	in	intracranial	self‐stimulation	(Ewan	
&	Martin,	 2011)	 and	 intravenous	 self‐administration	 (Martin,	 Kim,	
Buechler,	Porreca,	&	Eisenach,	2007)	when	animals	are	experienc-
ing	chronic	pain.	The	issue	is	difficult	to	untangle	in	paradigms	that	
do	not	provide	independent	measures	of	positive	and	negative	rein-
forcement	(i.e.,	drug	reward	vs.	relief	from	aversive	states	of	pain).	
We	recently	used	a	one‐sided	CPP	paradigm	(Bechara	et	al.,	1992;	
Bechara	 &	 Kooy,	 1992)	 to	 dissociate	 these	 two	 effects,	 revealing	
that	 the	negative	affective	states	associated	with	chronic	pain	are	
F I G U R E  6  Effects	of	dopamine	antagonism	on	morphine‐induced	anti‐nociception	during	early	(a,	b)	and	late	(c,	d)	phases	of	chronic	pain.	
Data	points	represent	mean	(±SD)	number	of	paw	withdrawals	(/10)	to	application	of	a	von	Frey	filament	(a,	c)	and	tail	flick	latencies	(b,	d)	in	
a	test	of	thermal	hyperalgesia.	Separate	groups	of	chronic	constriction	injury	(CCI)	and	sham‐lesioned	rats	were	injected	with	morphine	(2	or	
6	mg/kg)	combined	with	saline	or	SCH233390	(0.5	mg/kg)	prior	to	nociceptive	testing.	Testing	was	conducted	on	days	4–7	or	11–14	post‐
surgery	to	coincide	with	conditioned	place	preference	conditioning	sessions	in	early	and	late	phases	of	chronic	pain,	respectively.	Baseline	
(BL)	testing	occurred	1	day	prior	to	surgery
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alleviated	 through	 a	 mechanism	 involving	 kappa‐opioid	 receptors	
(Liu	et	al.,	2019).
As	expected,	mechanical	allodynia	intensified	following	CCI	sur-
gery,	manifested	as	increased	withdrawal	responses	in	the	ipsilateral	
paw	across	 testing.	Nociceptive	 responses	were	 lower	on	 the	 last	
test	day	in	CCI	rats	with	a	prior	history	of	SCH	23390	treatment,	but	
only	in	animals	tested	for	a	CPP	in	an	early	phase	of	chronic	pain.	It	
is	unlikely	that	this	change	impacted	measures	of	morphine	reward	
in	that	CPP	conditioning	and	testing	were	completed	1	week	prior	to	
the	last	nociceptive	test.	Repeated	administration	of	a	D2	receptor	
antagonist	 reduced	 final	day	pain	 scores	 in	both	experiments,	 but	
this	manipulation	 had	 no	 effect	 on	 a	morphine	CPP.	More	 impor-
tantly,	 subsequent	 testing	 confirmed	 that	 our	 drug	 regime	 which	
reduced	a	morphine	CPP	(i.e.,	high	dose	SCH	23390)	did	not	impact	
morphine‐induced	 analgesia	 in	 either	 chronic	 pain	 or	 pain‐naïve	
states.	It	is	unlikely,	therefore,	that	D1	receptor	blockade	disrupted	
reward	by	 altering	nociceptive	 responses	during	CPP	conditioning	
sessions.	This	is	consistent	with	a	lack	of	evidence	for	D1	receptor	
antagonists	 altering	 morphine‐induced	 analgesia	 in	 chronic	 pain,	
although	 these	 drugs	may	 attenuate	 the	 antinociceptive	 effect	 of	
opiates	 in	measures	 of	 acute	 (Flores,	 El	Banoua,	Galán‐Rodríguez,	
&	Fernandez‐Espejo,	2004)	or	tonic	(Altier	&	Stewart,	1999)	pain.
We	cannot	rule	out	the	possibility	that	DA	receptor	blockade	would	
disrupt	morphine	reward	at	later	time	points	post‐surgery,	as	functional	
changes	 in	DA	responses	 to	 rewarding	stimuli	continue	 to	evolve	up	
to	30	days	following	nerve	ligation	(Kato	et	al.,	2016).	We	selected	a	
shorter	 time	window	 for	 behavioral	 assessment	 because	nociceptive	
reflex	responses	 in	our	CCI	model	peak	by	day	10.	 It	 is	also	possible	
that	D1	receptor	antagonism	altered	locomotor	responses	to	morphine	
during	CPP	conditioning	sessions,	which	then	impacted	the	expression	
of	a	morphine	CPP.	This	seems	unlikely	given	that	central	infusions	of	
a	D1	receptor	antagonist	block	morphine	reward,	while	having	no	ef-
fect	on	morphine‐induced	locomotion	(Zarrindast	et	al.,	2003).	A	similar	
dissociation	 is	observed	 in	mice	 lacking	D1	 receptors	 (Urs,	Daigle,	&	
Caron,	2011),	although	these	effects	are	not	consistent	across	studies	
(Wang	et	al.,	2015).	Indeed,	there	is	debate	as	to	whether	the	genetic	
deletion	of	D1	receptors	blocks	a	morphine	CPP	(Urs	et	al.,	2011;	Wang	
et	al.,	2015),	possibly	reflecting	differences	in	developmental	adapta-
tions	that	impact	receptor	function	in	adulthood.
In	conclusion,	our	study	adds	to	evidence	for	pain‐induced	alter-
ations	in	reward	processing	and	suggests	that	changes	in	DA	D1	re-
ceptor	function	may	contribute	to	this	effect.	Identifying	mechanisms	
that	underlie	shifts	in	drug	reward	following	nerve	injury	may	help	to	
alleviate	 the	 devastating	 impacts	 of	 chronic	 pain,	which	 include	 re-
duced	quality	of	life	(Doth,	Hansson,	Jensen,	&	Taylor,	2010;	Langley,	
Van	Litsenburg,	Cappelleri,	&	Carroll,	2013)	and	exacerbation	of	co-
morbid	disorders,	such	as	anxiety	and	depression	(DosSantos,	Moura,	
&	DaSilva,	2017).	Few	patients	suffering	from	neuropathic	pain	receive	
adequate	treatment	(Torrance,	Ferguson,	&	Afolabi,	2013)	and	current	
pharmaceutical	 therapies	 show	 limited	 efficacy	 and	 large	 placebo	
responses	 for	 modest	 outcomes	 (Finnerup,	 Attal,	 &	 Haroutounian,	
2015).	Developing	compounds	that	target	altered	reward	processing	
may	be	a	more	fruitful	direction	for	treating	this	condition.
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